VT-6382

VT-6382 is a preclinical-stage, orally administered small molecule inhibitor of bile salt hydrolase (BSH) being developed by Vertero Therapeutics (formerly Axial Therapeutics). The compound is designed to modulate microbial bile acid metabolism and the gut environment to address bile acid dysregulation. As part of Vertero's pipeline focused on peripheral drivers of neurodegenerative diseases, VT-6382 aims to influence the gut-brain axis by targeting microbial enzymes in the gastrointestinal tract. While the specific therapeutic indication has not yet been disclosed, the drug represents a microbiome-targeted approach to treating systemic or neurological conditions driven by gut-derived metabolites.